On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

BackgroundInflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmunot...

Full description

Bibliographic Details
Main Authors:	Anning Xiong, Jianlin Xu, Shuyuan Wang, Runbo Zhong, Jun Lu, Tianqing Chu, Wei Zhang, Ying Li, Xiaoxuan Zheng, Baohui Han, Wei Nie, Hua Zhong, Xueyan Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-05-01
Series:	Frontiers in Immunology
Subjects:	lung immune prognostic index peripheral blood cells immune-checkpoint inhibitors combination chemotherapy non-small cell lung cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1173025/full

Similar Items

Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer
by: Liang Zheng, et al.
Published: (2023-01-01)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
by: Wen Kou, et al.
Published: (2022-10-01)

Predictive Value of LIPI and iSEND Immune Scoring System  in Immunotherapy of Advanced Non-small Cell Lung Cancer
by: Yiying LUO, et al.
Published: (2022-11-01)

Significance of the Lung Immune Prognostic Index for Assessment of the Reliability of the Clinical Treatment Outcome for Advanced Non-Small-Cell Lung Cancer in Patients with COVID-19 Infection
by: Kristina Krpina, et al.
Published: (2022-11-01)

Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer
by: Hongmu Li, et al.
Published: (2023-10-01)

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
by: Chunlan Chen, et al.
Published: (2023-04-01)

Efficacy and safety of anti‐PD‐1/PD‐L1 in combination with chemotherapy or not as first‐line treatment for advanced non‐small cell lung cancer: A systematic review and network meta‐analysis
by: Liming Wang, et al.
Published: (2022-02-01)

Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer
by: Zhong-Ning He, et al.
Published: (2023-10-01)

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study
by: Akihiro Yoshimura, et al.
Published: (2024-01-01)

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer
by: Bochen Sun, et al.
Published: (2022-11-01)

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
by: Wen-Fang Tang, et al.
Published: (2023-01-01)

Prognostic Value of the Lung Immune Prognostic Index for Metastatic Non-Small Cell Lung Cancer Patients: A Chinese Cohort Study
by: Huang J, et al.
Published: (2023-03-01)

Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer
by: Yuko Iida, et al.
Published: (2024-02-01)

Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade
by: Miriam Möller, et al.
Published: (2022-07-01)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
by: Jing Zhao, et al.
Published: (2023-02-01)

Development and validation of an immune‐related prognostic signature in lung adenocarcinoma
by: Sijin Sun, et al.
Published: (2020-08-01)

Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?
by: Carlo Putzu, et al.
Published: (2023-01-01)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
by: Kakeru Hisakane, et al.
Published: (2023-07-01)

Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting
by: Jacob Sands, et al.
Published: (2023-12-01)

Future Prospects of Immunotherapy in Non-Small-Cell Lung Cancer Patients: Is There Hope in Other Immune Checkpoints Targeting Molecules?
by: Natalia Krzyżanowska, et al.
Published: (2022-03-01)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
by: Lian Yu, et al.
Published: (2023-03-01)

Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient  Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus  Chemotherapy and Chemotherapy
by: Xinjuan WANG, et al.
Published: (2023-09-01)

A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
by: Dorthe Yakymenko, et al.
Published: (2023-01-01)

First-Line Treatments for Extensive-Stage Small-Cell Lung Cancer With Immune Checkpoint Inhibitors Plus Chemotherapy: A Network Meta-Analysis and Cost-Effectiveness Analysis
by: Shuo Kang, et al.
Published: (2022-01-01)

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
by: Jia Liu, et al.
Published: (2023-03-01)

Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis
by: Lupeng Qiu, et al.
Published: (2022-11-01)

Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
by: Parth Malik, et al.
Published: (2023-01-01)

Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis
by: He Wang, et al.
Published: (2022-09-01)

Remarkable response to PD-1 inhibitor in a patient with extensive-stage small cell lung cancer: a case report and literature review
by: Ge Yuan, et al.
Published: (2023-09-01)

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials
by: Wenjing Zhang, et al.
Published: (2024-04-01)

Immune Landscape and Classification in Lung Adenocarcinoma Based on a Novel Cell Cycle Checkpoints Related Signature for Predicting Prognosis and Therapeutic Response
by: Jian Yang, et al.
Published: (2022-05-01)

Front Line Applications and Future Directions of Immunotherapy in Small-Cell Lung Cancer
by: Selina K. Wong, et al.
Published: (2021-01-01)

Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
by: Shumin Yuan, et al.
Published: (2020-11-01)

Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer
by: Claudio Martin, et al.
Published: (2022-12-01)

Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer
by: Satomi Tanaka, et al.
Published: (2022-02-01)

PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer
by: Pournima Kadam, et al.
Published: (2020-06-01)

The earlier, the better? A review of neoadjuvant immunotherapy in resectable non‐small‐cell lung cancer
by: Fajiu Li, et al.
Published: (2022-06-01)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
by: Jing Wang, et al.
Published: (2023-04-01)

Early Changes in LIPI Score Predict Immune-Related Adverse Events: A Propensity Score Matched Analysis in Advanced Non-Small Cell Lung Cancer Patients on Immune Checkpoint Blockade
by: Fabrizio Nelli, et al.
Published: (2024-01-01)

Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes  Ratio to Predict the Response and Prognosis of Immunotherapy to  Advanced Lung Cancer
by: Hong LUO, et al.
Published: (2023-08-01)